NIH to fund antimicrobial resistance projects
Approximately $11 million has been awarded to nine projects that will allow the involved entities to develop diagnostic tools specifically targeting microorganisms that are resistant to antimicrobial treatment options. Special attention will be paid to agents that are prime causes of infections in hospitals, such as a staph infection.
“Antimicrobial resistance is a serious global health threat that is undermining our ability to effectively detect, treat and prevent infections,” NIAID Director Dr. Anthony S. Fauci said. “One way we can combat drug resistance is by developing enhanced diagnostic tests that rapidly identify the bacteria causing an infection and their susceptibility to various antimicrobials. This will help physicians determine the most effective treatments for infected individuals and thereby reduce the use of broad-spectrum antibiotics that can contribute to the drug resistance problem.”
As antimicrobial treatments have been utilized in the past 70 years, microorganisms have developed resistance measures to combat current options for treatment.
The NIAID claims that an average of 23,000 people die from an antimicrobial resistant infection annually.
The following institutions will be involved in this research: the University of California, Irvine; University of California, Berkeley; the Broad institute at MIT; Johns Hopkins University; First Light Biosciences Inc.; GeneFluidics Inc.; the Denver Health and Hospital Authority; Brigham Young University and BioFire Diagnostics, LLC.